Drug intelligence / Profile preview

Telixir20

Development stage: Unknown
Lead developer: BOL Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Telixir20** is a BOL Pharma marketed medicinal-cannabis drop product formulated as a high-THC cannabinoid preparation containing approximately 20% delta-9-tetrahydrocannabinol and 4% cannabidiol. It is supplied as a cannabinoid-based medicated drop formulation derived from whole-plant cannabis extract and/or isolated cannabinoids. The product is intended for severe acute pain, chronic pain, and palliative care, with therapeutic activity attributed broadly to cannabinoid-mediated pharmacology.

Brand names: Telixir20Telixir-20Telixir 20
Other names: BOL Telixir20

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Telixir20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telixir20.

Explore the full profile